- Home
- CCM vs BCAB Comparison
CCM vs BCAB Comparison
Compare CCM & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCM | BCAB |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 12.5M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CCM | BCAB |
|---|---|---|
| Price | $3.65 | $0.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 2.8K | ★ 1.5M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.13 |
| 52 Week High | $10.77 | $1.43 |
Technical Indicators
Market Signals| Indicator | CCM | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 41.77 |
| Support Level | $3.64 | $0.14 |
| Resistance Level | $5.86 | $0.27 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 38.96 | 19.32 |
Price Performance
Historical ComparisonAbout CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.